Squarepoint Ops LLC lifted its stake in Diplomat Pharmacy Inc (NYSE:DPLO) by 97.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 197,160 shares of the company’s stock after acquiring an additional 97,060 shares during the period. Squarepoint Ops LLC owned 0.26% of Diplomat Pharmacy worth $966,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of DPLO. Royal Bank of Canada raised its stake in shares of Diplomat Pharmacy by 184.8% in the 2nd quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Diplomat Pharmacy by 138.4% in the 2nd quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock valued at $70,000 after acquiring an additional 6,644 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of Diplomat Pharmacy in the 2nd quarter valued at approximately $77,000. State of Tennessee Treasury Department raised its stake in shares of Diplomat Pharmacy by 8.5% in the 3rd quarter. State of Tennessee Treasury Department now owns 24,855 shares of the company’s stock valued at $122,000 after acquiring an additional 1,954 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Diplomat Pharmacy by 22.7% in the 3rd quarter. California Public Employees Retirement System now owns 34,538 shares of the company’s stock valued at $169,000 after acquiring an additional 6,380 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

DPLO has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Deutsche Bank started coverage on Diplomat Pharmacy in a research note on Thursday, September 12th. They issued a “sell” rating and a $4.00 price objective on the stock. ValuEngine downgraded Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 5th. Raymond James downgraded Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a research report on Monday, December 9th. Finally, Barclays downgraded Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $7.00 to $3.00 in a research report on Wednesday, November 13th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company. Diplomat Pharmacy has a consensus rating of “Hold” and an average price target of $8.69.

Shares of NYSE DPLO opened at $3.93 on Friday. The company has a quick ratio of 0.36, a current ratio of 0.55 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $4.90 and its two-hundred day moving average is $5.21. The company has a market cap of $298.58 million, a P/E ratio of 19.65 and a beta of 0.92. Diplomat Pharmacy Inc has a 12 month low of $2.43 and a 12 month high of $14.77.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($2.15). The business had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.17 billion. Diplomat Pharmacy had a negative return on equity of 12.15% and a negative net margin of 12.47%. The firm’s quarterly revenue was down 5.3% on a year-over-year basis. Sell-side analysts expect that Diplomat Pharmacy Inc will post -0.92 earnings per share for the current fiscal year.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Management Fee

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.